Geron Aims For Fall Return To The Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Geron was the first stem cell therapy company to the clinic, with a plan to inject OPC1, made of embryonic glial progenitor cells, into the spinal cords of paralyzed patients. The idea is that once injected at the site of the nerve damage, the oligodendrocytes go to work rebuilding the insulating myelin sheath around the nerves and produce nerve growth factors called neutrophins that stimulate regrowth of nerve tissue.